Related Experiment Video
Updated: Feb 25, 2026

Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug
Published on: May 17, 2024
Managing Hypertension in the Elderly: What is Different, What is the Same?
1Cardiology Division, Department of Medicine, New York Medical College/Westchester Medical Center, Macy Pavilion, Room 141, Valhalla, NY, 10595, USA. wsaronow@aol.com.
Insights
Intensive blood pressure management in elderly adults significantly reduced cardiovascular events and mortality. Lowering systolic blood pressure to below 120 mmHg proved safe and effective in the SPRINT trial.
Area of Science:
- Gerontology
- Cardiovascular Medicine
- Clinical Trials
Background:
- Hypertension management in the elderly is complex.
- Previous guidelines suggested less intensive targets for older adults.
Purpose of the Study:
- To review the management of hypertension in elderly individuals.
- To present findings from the Systolic Blood Pressure Intervention Trial (SPRINT) relevant to elderly hypertension.
Main Methods:
- Analysis of the SPRINT trial data involving 2636 participants aged 75 years and older.
- Comparison of a systolic blood pressure goal of <120 mmHg versus <140 mmHg.
Main Results:
- Intensive treatment (SBP <120 mmHg) reduced major cardiovascular events by 34% and all-cause mortality by 33%.
- Heart failure incidence decreased by 38% with intensive treatment.
- Adverse event rates were comparable between intensive and standard treatment groups.
Conclusions:
- Lowering systolic blood pressure to <120 mmHg is effective and safe for elderly individuals with hypertension.
- Intensive blood pressure management benefits even frail elderly individuals.
Purpose Of Review:
The goal is to discuss management of hypertension in the elderly.
Recent Findings:
At 3.14-year follow-up of 2636 persons ≥75 years in the Systolic Blood Pressure Intervention Trial (SPRINT), compared with a systolic blood pressure (SBP) goal of <140 mmHg, a SBP goal of <120 mmHg reduced the primary endpoint of myocardial infarction, other acute coronary syndrome, stroke, heart failure, or cardiovascular death by 34% (p = 0.001), all-cause mortality by 33% (p = 0.009), heart failure by 38% (p = 0.003), and the primary outcome or death by 32% (p < 0.001). Absolute cardiovascular event rates were lower for the intensive treatment group within each frailty stratum. The incidence of serious adverse events was similar in both treatment groups. The SPRINT trial provides very important information on the efficacy and safety of lowering the SBP to <120 mmHg in elderly adults with hypertension.
Related Concept Videos
Hypertension V: Nursing Management
Drug Dosing: Geriatric Patients
Pharmacodynamics in Geriatric Patients: Effects of Age
Hypertension III: Clinical Manifestations and Diagnostic Studies
Hypertension I: Introduction
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution